Novo Nordisk enters 2026 on the defense as it faces a 'must-win' battle in the US market
The FDA approval of the Wegovy pill highlights many of the key themes Novo Nordisk will have to face in 2026.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments